GILD Latest Headlines

P/E Ratio Insights for Gilead Sciences

at www.benzinga.com (Fri, 27-Feb 5:00 PM)

FDA reportedly eyeing staff bonuses to accelerate drug reviews

at seekingalpha.com (Thu, 26-Feb 1:35 PM)

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Definium Therapeutics (DFTX)

at www.tipranks.com (Thu, 26-Feb 4:01 AM)

Gilead Sciences: Advancing Long-Acting HIV Franchise Underscores Competitive Edge and Supports Buy Rating

at www.tipranks.com (Wed, 25-Feb 9:16 PM)

ViiV says early-stage data on VH184 for HIV could support twice-yearly dosing

at seekingalpha.com (Wed, 25-Feb 3:50 PM)

Gilead phase 3 data shows continued viral suppression with HIV combo pill

at seekingalpha.com (Wed, 25-Feb 2:58 PM)

Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy

at www.benzinga.com (Wed, 25-Feb 10:09 AM)

Gilead: Strategic Arcellx Acquisition and Anito-cel Pipeline Strength Underpin Buy Rating and $162 Target

at www.tipranks.com (Wed, 25-Feb 5:06 AM)

Gilead’s $7.8 Billion Arcellx Deal Signals a Major Bet on Next-Generation Myeloma Therapy

Market Chameleon (Mon, 23-Feb 8:38 AM)

Gilead Sciences Strengthens Oncology Portfolio with 4% Sales Growth and Patent Protection Extension to 2036

Market Chameleon (Mon, 15-Dec 7:53 AM)